MedTrace Logo

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

NCT06617416 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2025-03-12

No results posted yet for this study

Summary

This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.

Conditions

  • NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG

Cadonilimab (AK104)

AK104 ivgtt Q3W

DRUG

Sugemalimab

1200mg Q3W

Sponsors & Collaborators

Principal Investigators

  • Jinming Yu, MD · Shandong Cancer Hospital and Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-12
Primary Completion
2026-10-28
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617416 on ClinicalTrials.gov